Therefore, it is wise to be aware of the facts that can impact the stock's prospects. Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the ...
Truist Financial’s price objective would suggest a potential ... and hedge funds own 90.96% of the company’s stock. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
JPMorgan lowered the firm’s price target on Vertex Pharmaceuticals (VRTX ... s “underwhelming” Phase 2 results and views the stock as “likely to work higher in 2025 with two key launches ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...